Significance of serum Her-2/neu oncoprotein, CA 15-3, and CEA in the clinical evaluation of metastatic breast cancer Journal Article
| Authors: | Dnistrian, A. M.; Schwartz, M. K.; Schwartz, D. C.; Ghani, F.; Kish, L. |
| Article Title: | Significance of serum Her-2/neu oncoprotein, CA 15-3, and CEA in the clinical evaluation of metastatic breast cancer |
| Abstract: | Serum Her-2/neu, CA 15-3 and CEA levels were measured in serial specimens from 54 women undergoing Herceptin® therapy for metastatic breast cancer. Tumor marker assays were performed on the Bayer Immuno 1® System, a random access automated immunochemistry analyzer. The upper limit of normal for serum Her-2/neu (15 ng/mL) was based on results obtained for 120 apparently healthy women, whereas reference values for CA 15-3 and CEA were conventional cutoff levels of 36 U/mL and 5 ng/mL, respectively. All patients had primary breast cancers that overexpressed tissue Her-2/neu by immunohistochemical technique. Pretreatment values of serum Her-2/neu were elevated in 36 patients (67%), CA 15-3 was elevated in 29 (54%), while CEA was abnormal in 23 (43%). When data for serum Her-2/neu and CA 15-3 were combined, the sensitivity for monitoring increased to 76%. Results for serum Her-2/neu may have significant predictive therapeutic implications; our data suggest that patients with abnormal pre-treatment serum Her-2/neu levels are more likely to respond to Herceptin therapy (83% response rate). |
| Keywords: | immunohistochemistry; adult; cancer chemotherapy; aged; major clinical study; conference paper; paclitaxel; sensitivity and specificity; gene overexpression; metastasis; breast cancer; carcinoembryonic antigen; automation; tumor marker; drug response; trastuzumab; immunochemistry; clinical examination; blood level; neu differentiation factor; ca 15-3 antigen; analyzer; human; female |
| Journal Title: | Journal of Clinical Ligand Assay |
| Volume: | 25 |
| Issue: | 2 |
| ISSN: | 1081-1672 |
| Publisher: | Clinical Ligand Assay Society |
| Date Published: | 2002-01-01 |
| Start Page: | 215 |
| End Page: | 220 |
| Language: | English |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Presented at the 28th Annual Meeting of the Clinical Ligand Assay Society; 2002 May; Houston, TX -- Export Date: 14 November 2014 -- Source: Scopus |
